Baltimore, Maryland 21231


Purpose:

This study will be looking at whether CY/GVAX in combination with SGI-110 is effective (recruits CD45RO+ T cells to the tumor which may be a marker of anti-tumor activity) and safe in patients with metastatic colon or rectum cancers.


Criteria:

Inclusion Criteria: 1. Documented cancer of the colon or rectum who have received and are stable on first or second-line therapy regimens for metastatic colorectal cancer 2. ECOG Performance Status of 0 to 1 3. Adequate organ function as defined by study-specified laboratory tests 4. Must use acceptable form of birth control through the study and for 28 days after final dose of study drug 5. Signed informed consent form 6. Willing and able to comply with study procedures Exclusion Criteria: 1. Currently have or have history of certain study-specified heart, liver, kidney, lung, neurological, immune or other medical conditions 2. Systemically active steroid use 3. Another investigational product within 28 days prior to receiving study drug 4. Major surgery or significant traumatic injury (or unhealed surgical wounds) occurring within 28 days prior to receiving study drug 5. Chemotherapy, radiation, hormonal, or biological cancer therapy within 28 days prior to receiving study drug 6. Pregnant or lactating 7. Unwilling or unable to comply with study procedures


NCT ID:

NCT01966289


Primary Contact:

Principal Investigator
Nilofer Azad, MD
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Carol Judkins, RN
Phone: 410-614-5241
Email: judkica@jhmi.edu


Backup Contact:

Email: nazad2@jhmi.edu
Nilofer Azad, MD


Location Contact:

Baltimore, Maryland 21231
United States

Carol Judkins, RN
Phone: 410-614-5241
Email: judkica@jhmi.edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: June 25, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.